logo

For the Inventor, By the Inventor

New York, NY, United States of America

XiaoXia Qian

This inventor holds 23 USPTO granted patents and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Merck Shapr & Dohme Corp.. Active years: 2001-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: XiaoXia Qian. Retrieved from https://idiyas.com/inventor/xiaoxia-qian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 23

% Patents Active = 91.3

 

Average Co-Inventor Count = 7.8

ph-index = 5

Forward Citations = 72(Granted Patents)


Company Filing History:

goldMedal16 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal6 out of 4,770 
 
Merck + Co., Inc.
 patents
bronzeMedal1 out of 1 
 
Merck Shapr & Dohme Corp.
 patent
4. 1 out of 10 
 
Msd R&d (China) Co., Ltd.
 patents
where one patent can have more than one assignee

Years Active: 2001-2019

Loading Chart...
Loading Chart...
Areas of Expertise:
PDE2 Inhibitors
Anti-Diabetic Agents
Antiprotozoal Agents
Aminotetrahydropyrans
Benzimidazole Derivatives
Cyclic Amines
Heterocyclic Compounds
Spirocyclic Compounds
Substituted Compounds
Diabetes Treatment
Amino Derivatives
Hexahydrofuro Compounds
23 patents (USPTO):Explore Patents
1. 10285989 - Pyrimidinone amide compounds as PDE2 inhibitors (2019-05-14),
2. 9868733 - Azabenzimidazole tetrahydrofuran derivatives (2018-01-16),
3. 9815796 - Pyrimidone carboxamide compounds as PDE2 inhibitors (2017-11-14),
4. 9717714 - Spirocyclic CETP inhibitors (2017-08-01),
5. 9556193 - Benzimidazole hexahydrofuro[3,2-b]furan derivatives (2017-01-31),
6. 9540364 - Benzimidazole tetrahydrofuran derivatives (2017-01-10),
7. 9527839 - Benzimidazole tetrahydropyran derivatives (2016-12-27),
8. 9382243 - Azabenzimidazole tetrahydropyran derivatives (2016-07-05),
9. 9290517 - Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives (2016-03-22),
10. 9221834 - Cyclic amine substituted oxazolidinone CETP inhibitor (2015-12-29),
11. 8980929 - Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes (2015-03-17),
12. 8853212 - Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes (2014-10-07),
13. 8796258 - Cyclic azabenzimidazole derivatives useful as anti-diabetic agents (2014-08-05),
14. 8653059 - Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes (2014-02-18),
15. 8455533 - Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes (2013-06-04),

Title: Innovations and Contributions of XiaoXia Qian

Introduction

XiaoXia Qian, based in New York, NY, is an accomplished inventor with a portfolio of 23 patents. His work primarily focuses on therapeutic agents aimed at treating a variety of neurological and psychiatric disorders. Throughout his career, he has made significant contributions to the field of medicinal chemistry.

Latest Patents

Among Qian's latest patents are the following innovations:

1. **Pyrimidinone Amide Compounds as PDE2 Inhibitors**: This invention involves pyrimidinone amide compounds that show promise as therapeutic agents for central nervous system and peripheral disorders linked to phosphodiesterase 2 (PDE2). These compounds are designed to treat various neurological and psychiatric conditions, including schizophrenia, psychosis, Alzheimer's disease, cognitive impairment, anxiety, depression, migraines, Huntington's disease, Parkinson's disease, and Parkinson's disease dementia (PDD).

2. **Azabenzimidazole Tetrahydrofuran Derivatives**: This patent details the development of novel compounds that act as activators of AMP-protein kinase. These compounds may be beneficial in treating, preventing, and managing diseases related to the activation of AMPK. They target conditions like Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

Career Highlights

XiaoXia Qian has a rich history in pharmaceutical research, having worked with globally recognized companies such as Merck Sharp & Dohme Corporation and Merck & Company, Inc. His expertise in the field has garnered him numerous patents and respect among his peers.

Collaborations

Throughout his career, Qian has collaborated with distinguished colleagues, including Tesfaye Biftu and Danqing D Feng. These partnerships have enhanced the innovative research methodologies and outcomes of their projects.

Conclusion

XiaoXia Qian is a notable innovator whose work has the potential to transform treatment approaches for numerous debilitating conditions. His extensive patent portfolio highlights his commitment to advancing medical science and improving patient outcomes through groundbreaking pharmaceutical innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…